Dexmedetomidine shortens agitation, not delirium, in non-intubated ICU patients
The 4D trial provides the first randomized placebo-controlled evidence that dexmedetomidine improves a composite of agitation, delirium, and intubation control in non-intubated hyperactive delirious ICU adults, though the driver is a roughly one-hour reduction in agitation duration.
Dexmedetomidine shows promise for delirium in non-intubated ICU patients.
Managing hyperactive delirium in non-intubated ICU patients is challenging, and current options are limited by side effects. Dexmedetomidine significantly reduced delirium symptoms compared to placebo, with fewer adverse effects reported. While promising, further studies are needed to confirm these findings across diverse patient groups and settings. Dexmedetomidine may be effective and safer for hyperactive delirium in non-intubated ICU patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Godet T, Louis C, Rieu B, De Jong A, Couhault P, Pradel G, Tête H, Bourguignon N, Borao L, Jabaudon M, Futier E, Jaber S, Pereira B, Chanques G, Constantin JM, 4D study group
Citation:Godet T, Louis C, Rieu B, et al. Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial. Intensive care medicine. 2025;51(12):2305-2317. doi:10.1007/s00134-025-08135-1
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.